Voir la source de Phenytoin: A Comprehensive Overview Of A Classic Antiepileptic Drug

<br>Phenytoin is a widely used anticonvulsant medication that has been a mainstay in the treatment of epilepsy since its introduction in the 1930s. It belongs to the hydantoin class of drugs and is primarily indicated for the management of partial seizures and generalized tonic-clonic seizures. Despite the development of newer antiepileptic drugs (AEDs) with improved tolerability and fewer interactions, phenytoin remains an important therapeutic option, particularly in resource-limited settings and for specific seizure types. This report summarizes the key pharmacological properties, clinical uses, adverse effects, and practical considerations associated with phenytoin therapy.<br><br><br><br>Mechanism of Action<br><br><br><br>Phenytoin exerts its antiepileptic effect primarily by stabilizing neuronal membranes and reducing repetitive firing of action potentials. The principal mechanism involves blockade of voltage-gated sodium channels in their inactivated state. By binding to the channel during the inactivated phase, phenytoin prolongs the refractory period and prevents the rapid, sustained depolarization that characterizes seizure activity. This use-dependent blockade is more pronounced in neurons undergoing high-frequency firing, which is typical of epileptic foci, while sparing normal neuronal activity. Additional mechanisms may include inhibition of calcium channels and modulation of neurotransmitter release, but sodium channel blockade is considered the primary mode of action.<br><br><br><br>Pharmacokinetics<br><br><br><br>Phenytoin exhibits complex, nonlinear pharmacokinetics that pose significant challenges in clinical management. After oral administration, absorption is slow but complete, with peak plasma concentrations reached 4 to 12 hours after a dose. The drug is highly protein-bound (approximately 90% to 95%) to albumin, and only the free (unbound) fraction is pharmacologically active. Phenytoin is extensively metabolized in the liver, primarily by the cytochrome P450 enzyme CYP2C9, with a minor contribution from CYP2C19. The major metabolite is 5-(4-hydroxyphenyl)-5-phenylhydantoin (HPPH), which is then glucuronidated and excreted in the urine.<br><br><br><br>A key feature of phenytoin is its saturable metabolism: at therapeutic concentrations, the metabolic enzymes become saturated, leading to zero-order kinetics. This means that small increases in dose can result in disproportionately large increases in plasma concentration, predisposing patients to toxicity. The elimination half-life is dose-dependent, typically ranging from 7 to 42 hours at low concentrations but increasing as saturation occurs. Consequently, therapeutic drug monitoring is essential to maintain plasma levels within the narrow therapeutic window of 10 to 20 μg/mL (total concentration) or 1 to 2 μg/mL (free concentration).<br><br><br><br>Clinical Uses<br><br><br><br>Phenytoin is approved for the treatment of partial seizures (including simple partial, complex partial, and secondarily generalized seizures) and primary generalized tonic-clonic seizures. It is not effective for absence seizures or myoclonic seizures and may even exacerbate these conditions. In the acute setting, intravenous phenytoin (or its prodrug fosphenytoin) is used for status epilepticus, although it has been largely replaced by newer agents such as levetiracetam or valproate due to faster onset and better tolerability. Phenytoin is also used off-label for trigeminal neuralgia and some cardiac arrhythmias, although these indications are less common.<br><br><br><br>Adverse Effects<br><br><br><br>Phenytoin is associated with a range of adverse effects, many of which are dose-dependent or related to long-term therapy. Acute dose-related effects include nystagmus, ataxia, dizziness, drowsiness, and slurred speech. At high plasma concentrations, encephalopathy and seizures may occur. Chronic use can lead to cosmetic changes such as hirsutism, gingival hyperplasia, coarsening of facial features, and acne. Gingival hyperplasia is particularly troublesome and may require good oral hygiene and regular dental care. Long-term therapy also increases the risk of osteoporosis due to altered vitamin D metabolism and reduced bone density.<br><br><br><br>Idiosyncratic reactions include hypersensitivity syndromes, such as Stevens-Johnson syndrome, [https://twitter.com/search?q=toxic%20epidermal toxic epidermal] necrolysis, and drug reaction with eosinophilia and systemic symptoms (DRESS), particularly in patients with certain human leukocyte antigen (HLA) alleles (e.g., HLA-B*1502 in Asian populations). Other serious adverse effects include hepatotoxicity, blood dyscrasias (e.g., agranulocytosis, aplastic anemia), and lymphadenopathy. Fetal exposure to phenytoin is associated with the fetal hydantoin syndrome,  [https://Beautyandcolours.it/ BautyFarmacia] characterized by craniofacial abnormalities, growth retardation, and developmental delay; therefore, it is contraindicated in pregnancy unless no safer alternative exists.<br><br><br><br>Drug Interactions<br><br><br><br>Phenytoin is a potent inducer of several cytochrome P450 enzymes (CYP3A4, CYP2C9, CYP2C19) and UDP-glucuronosyltransferases, leading to reduced efficacy of many coadministered drugs, including oral contraceptives, warfarin, corticosteroids, and other AEDs. Conversely, drugs that inhibit CYP2C9 or CYP2C19 (e.g., amiodarone, fluconazole, valproate) can increase phenytoin levels and precipitate toxicity. Phenytoin also has narrow therapeutic index, so any changes in concomitant medications warrant careful monitoring.<br><br><br><br>Therapeutic Drug Monitoring<br><br><br><br>Given its nonlinear pharmacokinetics and narrow window, routine monitoring of total and free phenytoin concentrations is recommended. Free level measurement is especially important in conditions associated with hypoalbuminemia (e.g., renal failure, liver disease, pregnancy) or in patients receiving other highly protein-bound drugs that may displace phenytoin. Target total levels are 10–20 μg/mL, but free levels of 1–2 μg/mL are more reliable in altered protein states. Dosing adjustments should be made cautiously, typically in small increments (e.g., 30 mg per day) and followed by level checks after 5–7 days to reach steady state.<br><br><br><br>Conclusion<br><br><br><br>Phenytoin remains a valuable antiepileptic drug despite its pharmacokinetic complexities and side effect profile. Its proven efficacy, low cost, and availability make it a first-line agent in many parts of the world, especially for generalized tonic-clonic and partial seizures. However, the need for therapeutic monitoring, potential for serious interactions, and tolerability issues necessitate careful patient selection and close clinical supervision. As newer AEDs with better safety profiles emerge, the role of phenytoin may continue to shift toward specific scenarios, but it will likely remain an important tool in the armamentarium against epilepsy for the foreseeable future.<br><br>